The report provides comprehensive information on the
therapeutics under development for Hypoglycemia, complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Hypoglycemia and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619282-hypoglycemia-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Hypoglycemia
- The report reviews pipeline therapeutics for Hypoglycemia
by companies and universities/research institutes based on information derived
from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypoglycemia
therapeutics and enlists all their major and minor projects
- The report assesses Hypoglycemia therapeutics based on
drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Hypoglycemia
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Hypoglycemia
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Hypoglycemia Overview 8
Therapeutics Development 9
Pipeline Products for Hypoglycemia - Overview 9
Hypoglycemia - Therapeutics under Development by Companies
10
Hypoglycemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Hypoglycemia - Products under Development by Companies 15
Hypoglycemia - Companies Involved in Therapeutics
Development 16
Biodel Inc. 16
Eiger BioPharmaceuticals, Inc. 17
Eli Lilly and Company 18
Heptares Therapeutics Limited 19
Novartis AG 20
Sanofi 21
SkyePharma Plc 22
Therakind Limited 23
USV Limited 24
XERIS Pharmaceuticals, Inc. 25
XOMA Corporation 26
Zealand Pharma A/S 27
Zosano Pharma Corporation 28
Hypoglycemia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Drug for Hypoglycemia - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
exendin-(9-39) - Drug Profile 39
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment